Merck & Co., Inc. (NYSE:MRK) Hits New 52-Week High – Still a Buy?

Merck & Co., Inc. (NYSE:MRK)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $137.98 and last traded at $135.3360, with a volume of 10283681 shares. The stock had previously closed at $135.97.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their individualized mRNA vaccine, used with Merck’s Keytruda, met the Phase 3 primary endpoint in high-risk melanoma. The combination improved recurrence-free survival and distant-metastasis-free survival compared with Keytruda alone, marking the first positive late-stage result for an mRNA cancer vaccine. The result could expand Merck’s oncology pipeline and help address the eventual loss of Keytruda exclusivity. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
• Positive Sentiment: Morgan Stanley upgraded MRK to overweight and raised its price target to $179 from $116, while UBS lifted its target to $175 and BMO raised its target to $170, reflecting increased confidence in the cancer-vaccine opportunity and Merck’s broader growth prospects. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Neutral Sentiment: Analysts cautioned that the initial results are not a complete regulatory or commercial victory. Full data, regulatory approval expected no earlier than 2027, manufacturing execution and the therapy’s eventual pricing and market adoption remain key uncertainties. Moderna’s Cancer Vaccine: Are Investors Putting The Cart Before The Horse?
• Negative Sentiment: RBC downgraded MRK to sector perform and set a $150 target, arguing that the roughly $150 valuation is unusually demanding for a company facing a major Keytruda loss of exclusivity in about two years. Jefferies also moved the stock to hold, creating a valuation overhang despite the trial success. Merck’s Cancer-Vaccine Trial Results Surpassed Expectations – So, Why Did RBC Downgrade MRK Stock?
• Negative Sentiment: Broader healthcare weakness and profit-taking after Merck’s sharp rally are adding pressure, while the stock’s elevated valuation leaves less room for disappointment. Sector Update: Healthcare Stocks Fall Thursday Afternoon

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wall Street Zen lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. JPMorgan Chase & Co. lifted their target price on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. CICC Research assumed coverage on Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an “outperform” rating and a $138.00 price target on the stock. Argus boosted their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Finally, Royal Bank Of Canada cut Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and increased their target price for the stock from $142.00 to $150.00 in a report on Thursday. Fifteen analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $142.10.

Merck & Co., Inc. Stock Down 1.9%

The company has a market cap of $368.23 billion, a P/E ratio of 119.40, a price-to-earnings-growth ratio of 6.56 and a beta of 0.19. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The firm’s 50 day moving average price is $127.43 and its 200-day moving average price is $121.01.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. During the same quarter in the previous year, the company posted $2.13 EPS. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts expect that Merck & Co., Inc. will post 2.77 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 272.00%.

Insider Buying and Selling

In other news, EVP Richard R. Deluca sold 11,699 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the transaction, the executive vice president directly owned 110,167 shares of the company’s stock, valued at $14,501,282.21. This trade represents a 9.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Jennifer Zachary sold 80,315 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the transaction, the executive vice president directly owned 45,509 shares of the company’s stock, valued at $6,073,631.14. This trade represents a 63.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is owned by company insiders.

Hedge Funds Weigh In On Merck & Co., Inc.

Institutional investors have recently modified their holdings of the business. Cascade Financial Partners LLC raised its holdings in shares of Merck & Co., Inc. by 0.5% in the 2nd quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock worth $1,895,000 after purchasing an additional 80 shares during the period. Somerset Trust Co increased its position in Merck & Co., Inc. by 0.9% during the 2nd quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock worth $1,118,000 after purchasing an additional 81 shares in the last quarter. Stonebridge Financial Group LLC increased its position in Merck & Co., Inc. by 0.9% during the 2nd quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock worth $1,124,000 after purchasing an additional 81 shares in the last quarter. Stronghold Wealth Management L.L.C. raised its holdings in Merck & Co., Inc. by 2.6% in the second quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company’s stock valued at $416,000 after buying an additional 82 shares during the period. Finally, Lederer & Associates Investment Counsel CA lifted its holdings in shares of Merck & Co., Inc. by 0.9% during the 2nd quarter. Lederer & Associates Investment Counsel CA now owns 9,603 shares of the company’s stock valued at $1,234,000 after acquiring an additional 84 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.